CAS: 152-97-6; Fluocortolone

该化合物是一种合成的花生类固醇,具有抗炎和免疫抑制特性,主要用于治疗各种炎和自体免疫性疾病,其特点是能够调节免疫反应,通过抑制炎性调节器的释放来减少炎症;氟甲诺酮的施用通常以乙酸衍生物的形式进行,这提高了其生物利用率和治疗效力;该物质与其他花生类动物相比,表现出相对较高的威力,使其在较低剂量下有效;其行动机制与甘醇类受体结合,导致基因表达方式的改变,最终导致发炎和免疫反应减少;氟甲诺酮经常被用于皮肤学,风湿气学和其他医疗领域,用于乙酰胺衍生物,皮质丝虫病和淋病性炎等疾病;然而,与其他园质类固醇相比,该物质可能具有副作用,包括潜在的肾上抑制,重量增生,以及感染后应变能力增加,在监测期间必须谨慎.

结构式图片

欧盟法规

REACH注册ECHA物质REACH预注册

上下游产品

6α-fluoro-11β,21-dihydroxy-16α-methylpregna-1,4-diene-3,20-dione 21-acetate

合成工艺路线路线简述

  • 合成目标产物 Fluocortolone 主要起始原料 Fluocortolone Acetate
  • (文献来源)合成步骤主要原料 Fluocortolone Acetate
📜氟可龙乙酸酯置于sodium Hydroxide体系中,用 甲醇,乙醇 用作溶剂,化学反应 1.5H,反应生成氟可龙
参考文献:一种氟可龙的制备方法
标题:一种氟可龙的制备方法
摘要:本发明涉及一种制备氟可龙的方法,其通过式i化合物的格氏反应,生成式ii的氟可龙.本发明制备氟可龙的方法线路简洁,操作简便,原料易得,生产成本和工业化条件大大降低.

海关参考信息

专利信息


专利号:US-12391691-B2
优先权日:2018-11-16
标题:Synthesis of key intermediate of KRAS G12C inhibitor compound
发明人:PARSONS ANDREW THOMAS; COCHRAN BRIAN MCNEIL; POWAZINIK IV WILLIAM; CAPORINI MARC ANTHONY
权利人:AMGEN INC
摘要:The present invention relates to an improved, efficient, scalable process to prepare intermediate compounds, such as compound 5M, having the structure n nuseful for the synthesis of compounds that target KRAS G12C mutations, such as

专利号:US-2025206736-A1
优先权日:2019-11-14
标题 :Synthesis of kras g12c inhibitor compound
发明人:CORBETT MICHAEL THOMAS; CAILLE SEBASTIEN
权利人:AMGEN INC
摘要:The present disclosure relates to an improved, efficient, scalable process to prepare intermediate compounds, such as 2-isopropyl-4-methylpyridin-3-amine, useful for the synthesis of compounds, such as Compound 9, for the treatment of KRAS G12C mutated cancers.

专利号:WO-2022226312-A1
优先权日:2021-04-22
标 题:Combination nucleotide pool depletion for treatment of viral infections and cancers
发明人:KUMAR VIKRAM; HESSON DAVID; DEMAREST JAMES
权利人:CLEAR CREEK BIO INC
摘要:The invention provides methods of treating cancers and viral infections by providing a combination of agents that inhibit both nucleotide synthesis and nucleotide salvage in the cells of a subject to prevent cancer proliferation and viral replication. The invention provides methods of depleting nucleotide pools by using both inhibitors of dihydroorotate dehydrogenase (DHODH), such as brequinar, which block synthesis of pyrimidine-based nucleotides, in combination of one or more nucleotide salvage inhibitors, for example deoxycytidine kinase (dCK) inhibitors, Equilibrative nucleoside transporter (ENT) inhibitors, and Uridine-cytidine kinase (UCK) inhibitors, which inhibit salvage of purine and/or pyrimidine-based nucleotides or nucleosides

专利号:US-9051302-B2
优先权日:2008-01-15
标 题 :Synthesis of resorcylic acid lactones useful as therapeutic agents
发明人:WINSSINGER NICOLAS; BARLUENGA SOFIA; KARPLUS MARTIN
权利人:WINSSINGER NICOLAS; BARLUENGA SOFIA; KARPLUS MARTIN; UNIV STRASBOURG
摘要:Disclosed are macrocyclic compounds of formulae I, I′, II, II′, III, III′, IV, and V, which are analogs of the pochonin resorcylic acid lactones, pharmaceutical compositions comprising the compounds, and methods and uses comprising the compounds for the treatment of diseases mediated by kinases and Heat Shock Protein 90 HSP90.

专利号:US-2024287041-A1
优先权日:2021-05-20
标题 :Methods of synthesis of heteroaryl derivatives of triazolyl acrylamides and crystalline forms
发明人:BALOGLU ERKAN; AUSTAD BRIAN C; ROE DAVID G; KEDUC ANDREW; GOTTSCHLING STEPHEN EDMUND; HECKER EVAN
权利人:KARYOPHARM THERAPEUTICS INC
摘要:The present invention relates to a method of preparing a compound represented by structural formula (VII), comprising reacting a compound represented by structural formula (II), with a compound represented by structural formula (III), in a solvent, in the presence of a Pd catalyst and one or more inorganic bases under conditions suitable to prepare a compound represented by structural formula (VII): The values and example values of the variables in structural formulas (VII), (II), and (III) are defined herein. The present invention also relates to crystalline Forms I and II of the compound represented by Structural Formula (VII), the use of the crystalline Forms in treating disease or disorders associated with CRM1 and method of preparing the crystalline Forms.

专利号:US-8926955-B2
优先权日:2008-12-22
标题 :Synthesis of polymer conjugates of indolocarbazole compounds
发明人:BAGNOD RAFFAELLA; BECCARIA LUCA; BERTARIONE RAVA ROSSA LUISA; CRISCUOLO DOMENICO; LORENZETTO CHIARA; MAINERO VALENTINA; MARCONI ALESSANDRA; PINCELLI CARLO; TRAVERSA SILVIO
权利人:BAGNOD RAFFAELLA; BECCARIA LUCA; BERTARIONE RAVA ROSSA LUISA; CRISCUOLO DOMENICO; LORENZETTO CHIARA; MAINERO VALENTINA; MARCONI ALESSANDRA; PINCELLI CARLO; TRAVERSA SILVIO; CREABILIS S A
摘要:The present invention relates to a process for the preparation of polymer conjugates of indolocarbaxole compounds, in particular of polymer conjugates of K-252a and derivatives thereof, by a synthetic route which results in a highly pure product, with a high product yield. In a further aspect the present invention relates to novel polymer conjugates of K-252a and derivatives thereof, wherein the chemical group linking the polymer unity to the K-252a or to the K-252a derivative compound is characterized by a 5-member oxazolidindionic cyclic structure. These novel polymer conjugates are obtained through the novel synthetic route with high purity and high yields.

供应商参考报价(招募中)

品牌试剂参考报价(招募中)

📌 第三方产品分析报告

✅ COA系统入驻 | 共享模式

主要参考文献


1: Cudina O, Brboric J, Vujic Z, Radulovic D, Vladimirov S. Determination of fluocortolone pivalate and fluocortolone hexanoate in suppositories using reverse-phase HPLC. Farmaco. 2000 Feb;55(2):125-7. doi: 10.3233/RNN-120292. doi: 10.1080/09546634.2017.1360988. Epub 2017 Sep 19. doi: 10.3109/08982104.2016.1149866. Epub 2016 Mar 9. doi: 10.1186/1546-0096-12-46. eCollection 2014. Review.
7: Freshwater DG. Fluocortolone. Br J Dermatol. 1967 Dec;79(12):729. German. German. doi: 10.1111/cod.12688. German. German. doi: 10.4274/tjo.93824. Epub 2017 Jan 17.
20: Eroğlu İ, Azizoğlu E, Özyazıcı M, Nenni M, Gürer Orhan H, Özbal S, Tekmen I, Ertam İ, Ünal İ, Özer Ö. Effective topical delivery systems for corticosteroids: dermatological and histological evaluations. Drug Deliv. 2016 Jun;23(5):1502-13. doi: 10.3109/10717544.2014.960981. Epub 2014 Sep 26.

合成参考文献


参考文献:10.1007/s00216-010-3484-3
摘要:Peters RJB, Oosterink JE, Stolker AAM, Georgakopoulos C, Nielen MWF. Generic sample preparation combined with high-resolution liquid chromatography–time-of-flight mass spectrometry for unification of urine screening in doping-control laboratories. Analytical and Bioanalytical Chemistry. 2010 Feb 16;396(7):2583–98. doi: 10.1007/s00216-010-3484-3.
📝 需求与反馈
尽可能描述清楚需求与问题信息
×

通知